FI3661510T3 - Menetelmiä käyttäytymismuutosten hoitamiseksi - Google Patents

Menetelmiä käyttäytymismuutosten hoitamiseksi Download PDF

Info

Publication number
FI3661510T3
FI3661510T3 FIEP18748921.6T FI18748921T FI3661510T3 FI 3661510 T3 FI3661510 T3 FI 3661510T3 FI 18748921 T FI18748921 T FI 18748921T FI 3661510 T3 FI3661510 T3 FI 3661510T3
Authority
FI
Finland
Prior art keywords
use according
pharmaceutical composition
compound
behavioral change
inhibitor
Prior art date
Application number
FIEP18748921.6T
Other languages
English (en)
Finnish (fi)
Inventor
Tamara Maes
Pozo David Rotllant
Ferre Christian Griñán
Lliberia Mercè Pallàs
Alemany Roser Nadal
García Antonio Armario
Original Assignee
Oryzon Genomics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics Sa filed Critical Oryzon Genomics Sa
Application granted granted Critical
Publication of FI3661510T3 publication Critical patent/FI3661510T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
FIEP18748921.6T 2017-08-03 2018-08-03 Menetelmiä käyttäytymismuutosten hoitamiseksi FI3661510T3 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17382544 2017-08-03
EP17382545 2017-08-03
EP18382299 2018-04-30
PCT/EP2018/071120 WO2019025588A1 (en) 2017-08-03 2018-08-03 METHODS OF TREATING ALTERATIONS IN BEHAVIOR

Publications (1)

Publication Number Publication Date
FI3661510T3 true FI3661510T3 (fi) 2024-12-18

Family

ID=63077881

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18748921.6T FI3661510T3 (fi) 2017-08-03 2018-08-03 Menetelmiä käyttäytymismuutosten hoitamiseksi

Country Status (22)

Country Link
US (2) US20200323828A1 (https=)
EP (2) EP3661510B1 (https=)
JP (2) JP2020529995A (https=)
KR (3) KR102912513B1 (https=)
CN (1) CN110996949A (https=)
AU (2) AU2018309372B2 (https=)
BR (1) BR112020000827A2 (https=)
DK (1) DK3661510T3 (https=)
ES (1) ES3001085T3 (https=)
FI (1) FI3661510T3 (https=)
HR (1) HRP20241716T1 (https=)
HU (1) HUE069697T2 (https=)
IL (1) IL272092B2 (https=)
LT (1) LT3661510T (https=)
MX (2) MX2020001323A (https=)
MY (1) MY204406A (https=)
PH (1) PH12020500211A1 (https=)
PL (1) PL3661510T3 (https=)
RS (1) RS66336B1 (https=)
SG (1) SG11202000077RA (https=)
SI (1) SI3661510T1 (https=)
WO (1) WO2019025588A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3017408C (en) 2016-03-15 2025-08-19 Oryzon Genomics, S.A. LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIS
US20220151999A1 (en) * 2019-03-20 2022-05-19 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
LT3941466T (lt) * 2019-03-20 2026-02-25 Oryzon Genomics, S.A. Vafidemstatas ribinio asmenybės sutrikimo simptomų, nesusijusių su agresija, gydymui
JP7681328B2 (ja) * 2019-09-03 2025-05-22 オリソン ヘノミクス，ソシエダ アノニマ 自閉症スペクトル障害の治療における使用のためのバフィデムスタット
WO2021058024A1 (zh) * 2019-09-29 2021-04-01 南京明德新药研发有限公司 Lsd1抑制剂
CN118604352B (zh) * 2024-05-22 2025-08-01 暨南大学 Vps13a表达促进剂在制备用于抑郁症诊断和治疗药物中的应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2007021839A2 (en) 2005-08-10 2007-02-22 Johns Hopkins University Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
EP2142287A4 (en) 2007-04-13 2012-05-23 Univ Johns Hopkins INHIBITORS OF LYSINPECIFIC DEMETHYLASE
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
JPWO2010143582A1 (ja) 2009-06-11 2012-11-22 公立大学法人名古屋市立大学 フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤
EP2467359A4 (en) 2009-08-18 2013-01-09 Univ Johns Hopkins (BIS-) UREA- AND (BIS-) THIOMINE COMPOUNDS AS EPIGENE MODULATORS OF THE LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF DISEASE TREATMENT THEREWITH
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
CA2796726C (en) 2010-04-19 2021-02-16 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
BR112012027062B8 (pt) 2010-04-20 2021-05-25 Fond Ieo composto, processo para a preparação de um composto e usos do mesmo
BR112013002164B1 (pt) 2010-07-29 2021-11-09 Oryzon Genomics S.A. Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
WO2012034116A2 (en) 2010-09-10 2012-03-15 The Johns Hopkins University Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012071469A2 (en) 2010-11-23 2012-05-31 Nevada Cancer Institute Histone demethylase inhibitors and uses thereof for treatment o f cancer
PH12013501871A1 (en) 2011-03-25 2019-06-03 Glaxosmithkline Ip No 2 Ltd Cyclopropylamines as lsd1 inhibitors
PE20141202A1 (es) 2011-08-09 2014-10-03 Takeda Pharmaceutical Compuesto de ciclopropanoamina
SI2744330T1 (sl) 2011-08-15 2020-11-30 University Of Utah Research Foundation Substituirani (E)-N'-(1-feniletiliden) benzohidrazidni analogi kot inhibitorji histon-demetilaze
US9289415B2 (en) 2011-09-01 2016-03-22 The Brigham And Women's Hospital, Inc. Treatment of cancer
JP6046154B2 (ja) 2011-10-20 2016-12-14 オリソン ヘノミクス エセ． アー． Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
CA2887598A1 (en) 2012-10-12 2014-04-17 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
WO2014084298A1 (ja) 2012-11-28 2014-06-05 京都府公立大学法人 リシン構造を有するｌｓｄ1選択的阻害薬
WO2014085613A1 (en) 2012-11-30 2014-06-05 Mccord Darlene E Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
EP2740474A1 (en) 2012-12-05 2014-06-11 Instituto Europeo di Oncologia S.r.l. Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
CN103054869A (zh) 2013-01-18 2013-04-24 郑州大学 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用
WO2014164867A1 (en) 2013-03-11 2014-10-09 Imago Biosciences Kdm1a inhibitors for the treatment of disease
BR112015032113B1 (pt) 2013-06-19 2019-01-29 University Of Utah Research Foundation análogos de (e)-n’-(1-feniletilideno)benzohidrazida substituídos como inibidores de histona demetilase
CN103319466B (zh) 2013-07-04 2016-03-16 郑州大学 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用
ES2734209T3 (es) 2013-08-06 2019-12-04 Imago Biosciences Inc Inhibidores de KDM1A para el tratamiento de enfermedades
US9186391B2 (en) 2013-08-29 2015-11-17 Musc Foundation For Research Development Cyclic peptide inhibitors of lysine-specific demethylase 1
WO2015031564A2 (en) 2013-08-30 2015-03-05 University Of Utah Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors
CA3161836A1 (en) 2013-12-11 2015-06-18 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
WO2015120281A1 (en) 2014-02-07 2015-08-13 Musc Foundation For Research Development Aminotriazole- and aminotetrazole-based kdm1a inhibitors as epigenetic modulators
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
EP3105218B1 (en) 2014-02-13 2019-09-25 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
CA2941716A1 (en) 2014-03-07 2015-09-11 The Johns Hopkins University Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
CN103893163B (zh) 2014-03-28 2016-02-03 中国药科大学 2-([1，1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用
MY180575A (en) 2014-04-11 2020-12-02 Takeda Pharmaceuticals Co Cyclopropanamine compound and use thereof
CN103961340B (zh) 2014-04-30 2019-06-25 南通中国科学院海洋研究所海洋科学与技术研究发展中心 一类lsd1抑制剂及其应用
KR102400920B1 (ko) 2014-05-01 2022-05-20 셀젠 콴티셀 리서치, 인크. 리신 특이적 데메틸라제-1의 억제제
WO2015181380A1 (en) 2014-05-30 2015-12-03 Ieo - Istituto Europeo Di Oncologia S.R.L. Cyclopropylamine compounds as histone demethylase inhibitors
CN104119280B (zh) 2014-06-27 2016-03-16 郑州大学 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用
DK3160956T3 (da) 2014-06-27 2020-08-31 Celgene Quanticel Res Inc Inhibitorer af lysin-specifik demethylase-1
FI3511319T3 (fi) 2014-07-03 2023-07-20 Celgene Quanticel Res Inc Lysiinispesifisen demetylaasi-1:n inhibiittoreita
JP6525422B2 (ja) 2014-07-03 2019-06-05 セルジーン クオンティセル リサーチ，インク． リジン特異的なデメチラーゼ−１の阻害剤
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
AU2015311805B2 (en) 2014-09-05 2020-04-02 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
EP2993175A1 (en) 2014-09-05 2016-03-09 IEO - Istituto Europeo di Oncologia Srl Thienopyrroles as histone demethylase inhibitors
WO2016123387A1 (en) 2015-01-30 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
CA2976350C (en) 2015-02-12 2023-09-19 Hugh Young Rienhoff, Jr. Kdm1a inhibitors for the treatment of disease
CN106146361A (zh) 2015-03-16 2016-11-23 四川大学 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
CN106045862B (zh) 2015-04-10 2019-04-23 上海迪诺医药科技有限公司 环丙胺类螺(杂)环化合物、其药物组合物及应用
US10526287B2 (en) 2015-04-23 2020-01-07 Constellation Pharmaceuticals, Inc. LSD1 inhibitors and uses thereof
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
WO2017004519A1 (en) 2015-07-02 2017-01-05 University Of Utah Research Foundation Substituted benzohydrazide analogs as histone demethylase inhibitors
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
LT3371152T (lt) 2015-11-05 2021-04-12 Celgene Quanticel Research, Inc. Kompozicijos, apimančios lizinui specifinės demetilazės-1 inhibitorių, turinčios pirimidino žiedą, ir jų panaudojimas vėžio gydymui
US10059668B2 (en) 2015-11-05 2018-08-28 Mirati Therapeutics, Inc. LSD1 inhibitors
EP3381896B1 (en) 2015-11-27 2023-01-18 Taiho Pharmaceutical Co., Ltd. Biphenyl compound or salt thereof
WO2017109061A1 (en) 2015-12-23 2017-06-29 Ieo - Istituto Europeo Di Oncologia S.R.L. Spirocyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
US9809541B2 (en) 2015-12-29 2017-11-07 Mirati Therapeutics, Inc. LSD1 inhibitors
RU2018127657A (ru) 2015-12-30 2020-01-31 Новартис Аг Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью
CN110267945A (zh) 2016-03-01 2019-09-20 诺华股份有限公司 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途
CN107200706A (zh) 2016-03-16 2017-09-26 中国科学院上海药物研究所 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途
US20170283397A1 (en) 2016-03-31 2017-10-05 University Of Utah Research Foundation Substituted 1-h-indol-3-yl-benzamide and 1, 1'-biphenyl analogs as histone demethylase inhibitors
PT3455204T (pt) 2016-05-09 2026-01-27 Jubilant Epicore LLC Compostos de ciclopropil-amida como inibidores duplos de lsd1/hdac
EP3246330A1 (en) 2016-05-18 2017-11-22 Istituto Europeo di Oncologia S.r.l. Imidazoles as histone demethylase inhibitors
CN107513068A (zh) 2016-06-16 2017-12-26 中国科学院上海药物研究所 一种具有fgfr抑制活性的新型化合物及其制备和应用
CN106478639B (zh) 2016-09-05 2018-09-18 郑州大学 嘧啶并1,2,4–三氮唑类的lsd1抑制剂、其制备方法及应用
CN106432248B (zh) 2016-09-27 2018-11-27 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用
WO2018081342A1 (en) 2016-10-26 2018-05-03 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
TWI753037B (zh) 2016-10-26 2022-01-21 美商星座製藥公司 Lsd1抑制劑及其用途
CN106831489B (zh) 2017-03-23 2018-04-17 郑州大学 苯环丙胺酰腙类化合物、制备方法及其应用
CN106928235A (zh) 2017-05-03 2017-07-07 郑州大学 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用

Also Published As

Publication number Publication date
RS66336B1 (sr) 2025-01-31
KR102912513B1 (ko) 2026-01-15
SI3661510T1 (sl) 2025-03-31
CN110996949A (zh) 2020-04-10
IL272092B1 (en) 2025-09-01
JP2020529995A (ja) 2020-10-15
MX2023009388A (es) 2023-08-23
AU2018309372A1 (en) 2020-01-30
LT3661510T (lt) 2025-01-27
BR112020000827A2 (pt) 2020-07-21
AU2018309372B2 (en) 2024-08-15
MX2020001323A (es) 2020-03-20
HRP20241716T1 (hr) 2025-02-14
EP4512473A3 (en) 2025-05-14
EP3661510A1 (en) 2020-06-10
IL272092A (en) 2020-03-31
SG11202000077RA (en) 2020-02-27
CA3071804A1 (en) 2019-02-07
US20200323828A1 (en) 2020-10-15
RU2020109167A (ru) 2021-09-03
KR20260015998A (ko) 2026-02-03
ES3001085T3 (es) 2025-03-04
RU2020109167A3 (https=) 2022-02-10
HUE069697T2 (hu) 2025-04-28
MY204406A (en) 2024-08-27
EP4512473A2 (en) 2025-02-26
IL272092B2 (en) 2026-01-01
WO2019025588A1 (en) 2019-02-07
EP3661510B1 (en) 2024-10-09
PH12020500211A1 (en) 2020-10-19
KR20200036920A (ko) 2020-04-07
KR102685898B1 (ko) 2024-07-19
US20240277673A1 (en) 2024-08-22
JP7829235B2 (ja) 2026-03-13
AU2024264660A1 (en) 2024-12-05
DK3661510T3 (da) 2025-01-02
PL3661510T3 (pl) 2025-04-14
KR20240122847A (ko) 2024-08-13
JP2023159354A (ja) 2023-10-31

Similar Documents

Publication Publication Date Title
FI3661510T3 (fi) Menetelmiä käyttäytymismuutosten hoitamiseksi
MX2024010140A (es) Nuevos metodos.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2022013410A (es) Metodos de tratamiento.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
TN2018000218A1 (en) Indole carboxamides compounds useful as kinase inhibitors.
MX2017010287A (es) Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n '-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]eta no-1,2-diamina.
EA201792116A1 (ru) Ингибитор янус-киназы
MX2021000148A (es) Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
RU2019100037A (ru) Способ лечения рассеянного склероза с использованием ингибитора lsd1
JP2020529995A5 (https=)
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
MX383665B (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
EA201691555A1 (ru) Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени
MX2015017629A (es) Combinaciones farmaceuticas.
MX389330B (es) Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.
CO2022005999A2 (es) Inhibidores del factor d del complemento para administración oral
MX390667B (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
MY199237A (en) Methods of treating ocular conditions
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
MX389088B (es) Métodos para tratar el vhc.